Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05262855

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma — FAPI-46 PDAC  

PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma

Clinical Trial Summary

This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05262855
Study type Interventional
Source SOFIE
Contact Sherly Mosessian, PH.D
Phone 818 324 1243
Email sherly.mosessian@sofie.com
Status Recruiting
Phase Phase 2
Start date May 2, 2022
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Recruiting NCT04700488 - Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) N/A
Not yet recruiting NCT05947825 - Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients Phase 2
Recruiting NCT06151223 - A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Recruiting NCT05845801 - Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
Recruiting NCT05853198 - Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability N/A
Recruiting NCT05669287 - Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics N/A
Recruiting NCT05727020 - Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Recruiting NCT05218889 - Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05132244 - Monitoring and Managing Glucose Levels in People With Pancreatic Cancer N/A
Recruiting NCT04365049 - Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma